IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis.

[1]  Subhashis Banerjee,et al.  Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. , 2012, The New England journal of medicine.

[2]  B. Strober,et al.  Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis , 2011, The British journal of dermatology.

[3]  J. Krueger,et al.  Contrasting pathogenesis of atopic dermatitis and psoriasis--part II: immune cell subsets and therapeutic concepts. , 2011, The Journal of allergy and clinical immunology.

[4]  J. Krueger,et al.  Contrasting pathogenesis of atopic dermatitis and psoriasis--part I: clinical and pathologic concepts. , 2011, The Journal of allergy and clinical immunology.

[5]  C. Bodemer,et al.  Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity , 2011, Science.

[6]  S. Chimenti,et al.  Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. , 2011, The Journal of investigative dermatology.

[7]  K. Peris,et al.  The IL23R R381Q Gene Variant Protects against Immune-Mediated Diseases by Impairing IL-23-Induced Th17 Effector Response in Humans , 2011, PloS one.

[8]  M. Suárez-Fariñas,et al.  Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. , 2010, The Journal of investigative dermatology.

[9]  P. Tak,et al.  Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis , 2010, Science Translational Medicine.

[10]  Andrew Johnston,et al.  Assessment of the psoriatic transcriptome in a large sample: additional regulated genes and comparisons with in vitro models. , 2010, The Journal of investigative dermatology.

[11]  A. Blauvelt,et al.  Circulating Th17, Th22, and Th1 cells are increased in psoriasis. , 2010, The Journal of investigative dermatology.

[12]  Mayte Suárez-Fariñas,et al.  Evaluation of the Psoriasis Transcriptome across Different Studies by Gene Set Enrichment Analysis (GSEA) , 2010, PloS one.

[13]  K. Gordon,et al.  Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. , 2010, Seminars in cutaneous medicine and surgery.

[14]  Mayte Suárez-Fariñas,et al.  Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. , 2009, The Journal of allergy and clinical immunology.

[15]  M. Gilliet,et al.  Self-RNA–antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8 , 2009, The Journal of experimental medicine.

[16]  Frank O. Nestle,et al.  Mechanisms of Disease: Psoriasis. , 2009 .

[17]  F. Nestle,et al.  The IL-23/Th17 axis in the immunopathogenesis of psoriasis. , 2009, The Journal of investigative dermatology.

[18]  Lisa C. Zaba,et al.  IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. , 2009, The Journal of allergy and clinical immunology.

[19]  M. McGeachy,et al.  Cytokines that regulate autoimmunity. , 2008, Current opinion in immunology.

[20]  J. Carucci,et al.  Low Expression of the IL-23/Th17 Pathway in Atopic Dermatitis Compared to Psoriasis1 , 2008, The Journal of Immunology.

[21]  Lisa C. Zaba,et al.  Th17 cytokines interleukin (IL)‐17 and IL‐22 modulate distinct inflammatory and keratinocyte‐response pathways , 2008, The British journal of dermatology.

[22]  James T. Elder,et al.  Induction of IL-17+ T Cell Trafficking and Development by IFN-γ: Mechanism and Pathological Relevance in Psoriasis1 , 2008, The Journal of Immunology.

[23]  Lisa C. Zaba,et al.  Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses , 2008, The Journal of Experimental Medicine.

[24]  Yihong Yao,et al.  Type I Interferon: Potential Therapeutic Target for Psoriasis? , 2008, PloS one.

[25]  A. Kimball,et al.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) , 2008, The Lancet.

[26]  Lisa C. Zaba,et al.  Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. , 2008, The Journal of investigative dermatology.

[27]  K. Wittkowski,et al.  Identification of Cellular Pathways of “Type 1,” Th17 T Cells, and TNF- and Inducible Nitric Oxide Synthase-Producing Dendritic Cells in Autoimmune Inflammation through Pharmacogenomic Study of Cyclosporine A in Psoriasis1 , 2008, The Journal of Immunology.

[28]  L. Fouser,et al.  IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. , 2008, The Journal of clinical investigation.

[29]  M. McGeachy,et al.  The link between IL-23 and Th17 cell-mediated immune pathologies. , 2007, Seminars in immunology.

[30]  Frank O. Nestle,et al.  Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis , 2007, Human Genetics.

[31]  James G. Krueger,et al.  Pathogenesis and therapy of psoriasis , 2007, Nature.

[32]  S. Sa,et al.  The Effects of IL-20 Subfamily Cytokines on Reconstituted Human Epidermis Suggest Potential Roles in Cutaneous Innate Defense and Pathogenic Adaptive Immunity in Psoriasis , 2007, The Journal of Immunology.

[33]  M. Lebwohl,et al.  A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. , 2007, The New England journal of medicine.

[34]  P. Valdez,et al.  Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis , 2007, Nature.

[35]  Steven J. Schrodi,et al.  A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. , 2007, American journal of human genetics.

[36]  L. Fouser,et al.  Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides , 2006, The Journal of experimental medicine.

[37]  K. Asadullah,et al.  IL‐22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis , 2006, European journal of immunology.

[38]  J. Bos,et al.  In Vitro and In Situ Expression of IL-23 by Keratinocytes in Healthy Skin and Psoriasis Lesions: Enhanced Expression in Psoriatic Skin , 2006, The Journal of Immunology.

[39]  A. Nakanishi,et al.  A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction , 2005, The British journal of dermatology.

[40]  A. Gurney,et al.  IL-22 Inhibits Epidermal Differentiation and Induces Proinflammatory Gene Expression and Migration of Human Keratinocytes1 , 2005, The Journal of Immunology.

[41]  K. Ley,et al.  Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. , 2005, Immunity.

[42]  K. Wittkowski,et al.  Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[43]  R. Wu,et al.  IL-17 Markedly Up-Regulates β-Defensin-2 Expression in Human Airway Epithelium via JAK and NF-κB Signaling Pathways1 , 2004, The Journal of Immunology.

[44]  K. Asadullah,et al.  IL-22 increases the innate immunity of tissues. , 2004, Immunity.

[45]  James G Krueger,et al.  Combining several ordinal measures in clinical studies , 2004, Statistics in medicine.

[46]  M. Dhodapkar,et al.  Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris , 2004, The Journal of experimental medicine.

[47]  Wing Hung Wong,et al.  Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. , 2003, Physiological genomics.

[48]  D. Conklin,et al.  Interleukin 20 Discovery, Receptor Identification, and Role in Epidermal Function , 2001, Cell.

[49]  G. Weinstein,et al.  Treatment of psoriasis. , 1976, The New England journal of medicine.

[50]  N. J. Eungdamrong,et al.  Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. , 2009, The Journal of investigative dermatology.

[51]  B. Strober,et al.  Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. , 2008, Journal of the American Academy of Dermatology.

[52]  T. Yamamura,et al.  Th17 Cells and autoimmune encephalomyelitis (EAE/MS). , 2008, Allergology international : official journal of the Japanese Society of Allergology.

[53]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[54]  BMC Bioinformatics Methodology article "Harshlighting " small blemishes on microarrays , 2005 .